Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?

European Heart Journal

Volumn 27, Issue 18, 2006, Pages 2154-2157

  Fox, Kim ^a   Ferrari, Roberto ^b   Yusuf, Salim ^c   Borer, Jeffrey S ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ACE inhibitors; Secondary prevention; Stable coronary artery disease

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; RAMIPRIL; TRANDOLAPRIL;

ANGINA PECTORIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; HUMANS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 33748807757     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl122     Document Type: Review

References (22)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
2. Fox KM; European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
3. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL, PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
4. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127-137.
5. Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease. N Engl J Med 2005;352:937-939.
6. Pfeffer MA, Domanski M, Rosenberg Y, Verter J, Geller N, Albert P, Hsia J, Braunwald E. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol 1998;82:25H-30H.
7. Henderson RA, Pocock SJ, Clayton TC; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-1170.
8. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, Morris C, Mathur V, Varnauskas E, Chalmer TC. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563-570.
9. Rihal CS, Raco DL, Gersh BJ, Yusuf S. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. Circulation 2003;108:2439-2445.
10. Oubina MP, de las Heras N, Cediel E, Sanz-Rosa D, Aragoncillo P, Diaz C, Hernandez G, Lahera V, Cachofeiro V. Synergistic effect of angiotensin- converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond) 2003;105:655-662.
11. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Elisaf M; GREACE Study Collaborative Group. Effects of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781-788.
12. Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P, Magi A, Yusuf S. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 2004;43:2200-2206.
13. Arnold JM, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, Lonn E, Pogue J, Bosch J; HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003;107:1284-1290.
14. Borer JS, Somberg JC. Angiotensin converting enzyme inhibitors for mortality reduction in congestive heart failure: should approval be granted for a class effect? In: Borer JS, Somberg J, eds. Cardiovascular Drug Development. New York, NY: Marcel Dekker; 1999. p63-70.
15. Borer JS. Development of cardiovascular drugs: The US regulatory milieu from the perspective of a participating nonregulator. J Am Coll Cardiol 2004;44:2285-2292.
16. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
17. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin- converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: A systematic review and meta-analysis of randomised controlled trials. J Am Coll Cardiol 2006;47:1576-1583.
18. Danchin N, Cucherat, Thuillez C, Durand E, Kadri Z, Steg PG. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction. Arch Intern Med 2006;166:787-796.
19. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combination of three trials. Lancet 2006;368:581-588.
20. Smith MG, Neville AM, Middleton JC. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study. Intern Med J 2003;33:414-419.
21. Schadlich PK, Brecht JG, Rangoonwala B, Huppertz E. Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective. Pharmacoeconomics 2004;22:955-973.
22. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: Executive Summary. Eur Heart J 2006;27:1341-1381.